1. Home
  2. QSR vs BIIB Comparison

QSR vs BIIB Comparison

Compare QSR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Restaurant Brands International Inc.

QSR

Restaurant Brands International Inc.

HOLD

Current Price

$67.90

Market Cap

24.9B

Sector

N/A

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$177.23

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSR
BIIB
Founded
1954
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.9B
24.2B
IPO Year
2006
1991

Fundamental Metrics

Financial Performance
Metric
QSR
BIIB
Price
$67.90
$177.23
Analyst Decision
Buy
Buy
Analyst Count
17
22
Target Price
$73.94
$177.40
AVG Volume (30 Days)
2.7M
2.3M
Earning Date
02-11-2026
02-11-2026
Dividend Yield
3.63%
N/A
EPS Growth
N/A
N/A
EPS
2.81
10.97
Revenue
$9,264,000,000.00
$10,065,900,000.00
Revenue This Year
$12.57
$3.58
Revenue Next Year
$3.92
N/A
P/E Ratio
$24.32
$16.04
Revenue Growth
16.82
4.77
52 Week Low
$58.71
$110.04
52 Week High
$73.70
$185.17

Technical Indicators

Market Signals
Indicator
QSR
BIIB
Relative Strength Index (RSI) 38.42 57.95
Support Level $68.80 $175.00
Resistance Level $70.05 $178.46
Average True Range (ATR) 0.91 3.50
MACD -0.37 -0.44
Stochastic Oscillator 21.03 86.16

Price Performance

Historical Comparison
QSR
BIIB

About QSR Restaurant Brands International Inc.

Restaurant Brands generates about $44 billion in system sales across more than 32,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,082 stores), Tim Hortons (4,539), Popeyes (3,520), and Firehouse Subs (1,345), concentrated in the US and Canada, with these brands also comprising 15,639 franchised international locations as of year-end 2024. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: